The role of quantitative hepatitis B surface antigen revisited

Journal of Hepatology

Volumn 66, Issue 2, 2017, Pages 398-411

  Cornberg, Markus ^a   Wong, Vincent Wai Sun ^b   Locarnini, Stephen ^c   Brunetto, Maurizia ^d   Janssen, Harry L A ^e   Chan, Henry Lik Yuen ^b  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Antiviral treatment; Entecavir; HBsAg; Hepatitis B; Pegylated interferon; Tenofovir

Indexed keywords

CIRCULAR DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA; VIRUS DNA;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; DISEASE ACTIVITY; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT RESPONSE; DISEASE MANAGEMENT; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; SEROLOGY; VIROLOGY;

DISEASE MANAGEMENT; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; SEROLOGIC TESTS;

EID: 85006106499     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.009     Document Type: Review

References (124)

1. [1] Werle-Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004), 1750–1758.
2. [2] Chan, H.L., Wong, V.W., Tse, A.M., Tse, C.H., Chim, A.M., Chan, H.Y., et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 5 (2007), 1462–1468.
3. [3] Chan, H.L., Thompson, A., Martinot-Peignoux, M., Piratvisuth, T., Cornberg, M., Brunetto, M.R., et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 55 (2011), 1121–1131.
4. [4] Locarnini, S., Hatzakis, A., Chen, D.S., Lok, A., Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol 62 (2015), S76–S86.
5. [5] Heermann, K.H., Goldmann, U., Schwartz, W., Seyffarth, T., Baumgarten, H., Gerlich, W.H., Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 52 (1984), 396–402.
6. [6] Lenhoff, R.J., Summers, J., Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J Virol 68 (1994), 4565–4571.
7. [7] Bruss, V., Hepatitis B virus morphogenesis. World J Gastroenterol 13 (2007), 65–73.
8. [8] Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 1, 2012, e00049.
9. [9] Gerlich, W.H., Medical virology of hepatitis B: how it began and where we are now. Virol J, 10, 2013, 239.
10. [10] Bock, C.T., Schranz, P., Schröder, C.H., Zentgraf, H., Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 8 (1994), 215–229.
11. [11] Newbold, J.E., Xin, H., Tencza, M., Sherman, G., Dean, J., Bowden, S., et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69 (1995), 3350–3357.
12. [12] Bill, C.A., Summers, J., Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration. Proc Natl Acad Sci U S A 101 (2004), 11135–11140.
13. [13] Yang, W., Summers, J., Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination. J Virol 69 (1995), 4029–4036.
14. [14] Gong, S.S., Jensen, A.D., Wang, H., Rogler, C.E., Duck hepatitis B virus integrations in LMH chicken hepatoma cells: identification and characterization of new episomally derived integrations. J Virol 69 (1995), 8102–8108.
15. [15] Revill, P., Testoni, B., Locarnini, S., Zoulim, F., Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol 13 (2016), 239–248.
16. [16] Woodell, C., Chavez, D., Goetzmann, J.E., Guerra, B., Peterson, R.M., Lee, H., et al. Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg. Hepatology 62 (2015), 222A–223A.
17. [17] Lin, L.Y., Wong, V.W., Zhou, H.J., Chan, H.Y., Gui, H.L., Guo, S.M., et al. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol 82 (2010), 1494–1500.
18. [18] Thompson, A.J., Nguyen, T., Iser, D., Ayres, A., Jackson, K., Littlejohn, M., et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51 (2010), 1933–1944.
19. [19] Manesis, E.K., Papatheodoridis, G.V., Tiniakos, D.G., Hadziyannis, E.S., Agelopoulou, O.P., Syminelaki, T., et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 55 (2011), 61–68.
20. [20] Warner, N., Locarnini, S., The antiviral drug selected hepatitis B virus rtA181T/sW172∗ mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48 (2008), 88–98.
21. [21] Warner, N., Locarnini, S., Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?. Antivir Ther 14 (2009), 139–142.
22. [22] Gerlich, W., Thomssen, R., Standardized detection of hepatitis B surface antigen: determination of its serum concentration in weight units per volume. Dev Biol Stand 30 (1975), 78–87.
23. [23] Burdino, E., Ruggiero, T., Proietti, A., Milia, M.G., Olivero, A., Caviglia, G.P., et al. Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays. J Clin Virol 60 (2014), 341–346.
24. [24] Wursthorn, K., Jaroszewicz, J., Zacher, B.J., Darnedde, M., Raupach, R., Mederacke, I., et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 50 (2011), 292–296.
25. [25] Liao, C.C., Hsu, C.W., Gu, P.W., Yeh, C.T., Lin, S.M., Chiu, C.T., Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients. Biomed J 38 (2015), 250–256.
26. [26] Verheyen, J., Neumann-Fraune, M., Berg, T., Kaiser, R., Obermeier, M., The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. J Clin Virol 54 (2012), 279–281.
27. [27] Madalinski, K., Burczynska, B., Heermann, K.H., Uy, A., Gerlich, W.H., Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol 84 (1991), 493–500.
28. [28] Rinker, F., Bremer, C., Bremer, B., Manns, M.P., Wedemeyer, H., Yang, L., et al. Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients. J Hepatol 62 (2015), S524–S525.
29. [29] Seeger, C., Mason, W.S., Molecular biology of hepatitis B virus infection. Virology 479–480 (2015), 672–686.
30. [30] Sugiyama, M., Tanaka, Y., Kato, T., Orito, E., Ito, K., Acharya, S.K., et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44 (2006), 915–924.
31. [31] Sonneveld, M.J., Hansen, B.E., Piratvisuth, T., Jia, J.D., Zeuzem, S., Gane, E., et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 58 (2013), 872–880.
32. [32] Brunetto, M.R., Marcellin, P., Cherubini, B., Yurdaydin, C., Farci, P., Hadziyannis, S.J., et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 59 (2013), 1153–1159.
33. [33] Pollicino, T., Amaddeo, G., Restuccia, A., Raffa, G., Alibrandi, A., Cutroneo, G., et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology 56 (2012), 434–443.
34. [34] Jaroszewicz, J., Calle Serrano, B., Wursthorn, K., Deterding, K., Schlue, J., Raupach, R., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 52 (2010), 514–522.
35. [35] Nguyen, T., Thompson, A.J., Bowden, S., Croagh, C., Bell, S., Desmond, P.V., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52 (2010), 508–513.
36. [36] Gerlich, W., Stamm, B., Thomssen R (Trans.) Prognostic significance of quantitative HBsAg determination in acute hepatitis B. Partial report of a cooperative clinical study of the DFG-focus of “virus hepatitis” Verh Dtsch Ges Inn Med 83 (1977), 554–557.
37. [37] Chan, H.L., Wong, V.W., Wong, G.L., Tse, C.H., Chan, H.Y., Sung, J.J., A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52 (2010), 1232–1241.
38. [38] Seto, W.K., Wong, D.K., Fung, J., Ip, P.P., Yuen, J.C., Hung, I.F., et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS ONE, 7, 2012, e43087.
39. [39] Martinot-Peignoux, M., Carvalho-Filho, R., Lapalus, M., Netto-Cardoso, A.C., Lada, O., Batrla, R., et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. J Hepatol 58 (2013), 1089–1095.
40. [40] Xun, Y.H., Zang, G.Q., Guo, J.C., Yu, X.L., Liu, H., Xiang, J., et al. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroenterol Hepatol 28 (2013), 1746–1755.
41. [41] Goyal, S.K., Jain, A.K., Dixit, V.K., Shukla, S.K., Kumar, M., Ghosh, J., et al. HBsAg level as predictor of liver fibrosis in HBeAg positive patients with chronic hepatitis B virus infection. J Clin Exp Hepatol 5 (2015), 213–220.
42. [42] Fung, J., Seto, W.K., Wong, D.K., Lai, C.L., Yuen, M.F., Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study. Liver Int 35 (2015), 854–859.
43. [43] Tseng, T.C., Liu, C.J., Su, T.H., Wang, C.C., Chen, C.L., Chen, P.J., et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 141 (2011), 517–525, 525.e1.
44. [44] Fung, J., Wong, D.K., Seto, W.K., Kopaniszen, M., Lai, C.L., Yuen, M.F., Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis. Am J Gastroenterol 109 (2014), 1764–1770.
45. [45] Brunetto, M.R., Oliveri, F., Coco, B., Leandro, G., Colombatto, P., Gorin, J.M., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36 (2002), 263–270.
46. [46] Brunetto, M.R., Oliveri, F., Colombatto, P., Moriconi, F., Ciccorossi, P., Coco, B., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139 (2010), 483–490.
47. [47] Liu, J., Yang, H.I., Lee, M.H., Jen, C.L., Batrla-Utermann, R., Lu, S.N., et al. Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression. Hepatology 64 (2016), 381–389.
48. [48] Lee, M.H., Yang, H.I., Liu, J., Batrla-Utermann, R., Jen, C.L., Iloeje, U.H., et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 58 (2013), 546–554.
49. [49] Tseng, T.C., Liu, C.J., Yang, H.C., Su, T.H., Wang, C.C., Chen, C.L., et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 57 (2013), 441–450.
50. [50] Tseng, T.C., Liu, C.J., Yang, H.C., Su, T.H., Wang, C.C., Chen, C.L., et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142 (2012), 1140–1149, e3 (Quiz e13).
51. [51] Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up. Clin Gastroenterol Hepatol, 2016, 10.1016/j.cgh.2016.01.019.
52. [52] Tseng, T.C., Liu, C.J., Yang, H.C., Su, T.H., Wang, C.C., Chen, C.L., et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 55 (2012), 68–76.
53. [53] Chan, H.L., Wong, G.L., Tse, C.H., Chan, H.Y., Wong, V.W., Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 204 (2011), 408–414.
54. [54] Liu, J., Lee, M.H., Batrla-Utermann, R., Jen, C.L., Iloeje, U.H., Lu, S.N., et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 58 (2013), 853–860.
55. [55] Zeng, L.Y., Lian, J.S., Chen, J.Y., Jia, H.Y., Zhang, Y.M., Xiang, D.R., et al. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study. World J Gastroenterol 20 (2014), 9178–9184.
56. [56] Wursthorn, K., Lutgehetmann, M., Dandri, M., Volz, T., Buggisch, P., Zollner, B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44 (2006), 675–684.
57. [57] Janssen, H.L., Kerhof-Los, C.J., Heijtink, R.A., Schalm, S.W., Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 23 (1994), 251–257.
58. [58] Arends, P., Rijckborst, V., Zondervan, P.E., Buster, E., Cakaloglu, Y., Ferenci, P., et al. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline. J Viral Hepat 21 (2014), 897–904.
59. [59] Sonneveld, M.J., Rijckborst, V., Boucher, C.A., Hansen, B.E., Janssen, H.L., Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 52 (2010), 1251–1257.
60. [60] Lau, G.K.K., Marcellin, P., Brunetto, M., Piratvisuth, T., Kapprell, H.P., Messinger, D., et al. On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol, 50, 2009, S333.
61. [61] Sonneveld, M.J., Arends, P., Boonstra, A., Hansen, B.E., Janssen, H.L., Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol 58 (2013), 898–903.
62. [62] Sonneveld, M.J., Rijckborst, V., Zeuzem, S., Heathcote, E.J., Simon, K., Senturk, H., et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 56 (2012), 67–75.
63. [63] Sonneveld, M.J., Rijckborst, V., Cakaloglu, Y., Simon, K., Heathcote, E.J., Tabak, F., et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype. Antivir Ther 17 (2012), 9–17.
64. [64] Chan, H.L., Wong, V.W., Chim, A.M., Chan, H.Y., Wong, G.L., Sung, J.J., Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 32 (2010), 1323–1331.
65. [65] Gane, E., Jia, J., Han, K., Tanwandee, T., Chuang, W.L., Marcellin, P., et al. Neptune study: On-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients. J Hepatol, 54, 2011, S31.
66. [66] EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
67. [67] Marcellin, P., Bonino, F., Lau, G.K., Farci, P., Yurdaydin, C., Piratvisuth, T., et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136 (2009), 2169–2179, e1.
68. [68] Rijckborst, V., Ferenci, P., Akdogan, M., Pinarbasi, B., ter Borg, M.J., Simon, K., et al. Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders. Eur J Gastroenterol Hepatol 24 (2012), 1012–1019.
69. [69] Brunetto, M.R., Moriconi, F., Bonino, F., Lau, G.K., Farci, P., Yurdaydin, C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49 (2009), 1141–1150.
70. [70] Rijckborst, V., Hansen, B.E., Cakaloglu, Y., Ferenci, P., Tabak, F., Akdogan, M., et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52 (2010), 454–461.
71. [71] Marcellin, P., Bonino, F., Yurdaydin, C., Hadziyannis, S., Moucari, R., Kapprell, H.P., et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 7 (2013), 88–97.
72. [72] Rijckborst, V., Hansen, B.E., Ferenci, P., Brunetto, M.R., Tabak, F., Cakaloglu, Y., et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 56 (2012), 1006–1011.
73. [73] Goulis, I., Karatapanis, S., Akriviadis, E., Deutsch, M., Dalekos, G.N., Raptopoulou-Gigi, M., et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int 35 (2015), 1540–1548.
74. [74] Cornberg, M., Honer Zu Siederdissen, C., HBsAg seroclearance with NUCs: rare but important. Gut 63 (2014), 1208–1209.
75. [75] Reijnders, J.G., Perquin, M.J., Zhang, N., Hansen, B.E., Janssen, H.L., Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 139 (2010), 491–498.
76. [76] Manesis, E.K., Hadziyannis, E.S., Angelopoulou, O.P., Hadziyannis, S.J., Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 12 (2007), 73–82.
77. [77] Reijnders, J.G., Rijckborst, V., Sonneveld, M.J., Scherbeijn, S.M., Boucher, C.A., Hansen, B.E., et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 54 (2011), 449–454.
78. [78] Chevaliez, S., Hezode, C., Bahrami, S., Grare, M., Pawlotsky, J.M., Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely. J Hepatol 58 (2013), 676–683.
79. [79] Zoutendijk, R., Hansen, B.E., van Vuuren, A.J., Boucher, C.A., Janssen, H.L., Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 204 (2011), 415–418.
80. [80] Seto, W.K., Hui, A.J., Wong, V.W., Wong, G.L., Liu, K.S., Lai, C.L., et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 64 (2014), 667–672.
81. [81] Zoulim, F., Carosi, G., Greenbloom, S., Mazur, W., Nguyen, T., Jeffers, L., et al. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol 62 (2015), 56–63.
82. [82] Seto, W.K., Liu, K., Wong, D.K., Fung, J., Huang, F.Y., Hung, I.F., et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 59 (2013), 709–716.
83. [83] Jaroszewicz, J., Ho, H., Markova, A., Deterding, K., Wursthorn, K., Schulz, S., et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 16 (2011), 915–924.
84. [84] Papatheodoridis, G., Triantos, C., Hadziyannis, E., Zisimopoulos, K., Georgiou, A., Voulgaris, T., et al. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate. J Viral Hepat 22 (2015), 1079–1087.
85. [85] Xia, Y., Stadler, D., Lucifora, J., Reisinger, F., Webb, D., Hösel, M., et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 150 (2016), 194–205.
86. [86] Wursthorn, K., Jung, M., Riva, A., Goodman, Z.D., Lopez, P., Bao, W., et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52 (2010), 1611–1620.
87. [87] Marcellin, P., Buti, M., Krastev, Z., de Man, R.A., Zeuzem, S., Lou, L., et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 61 (2014), 1228–1237.
88. [88] Lee, M.H., Lee da, M., Kim, S.S., Cheong, J.Y., Cho, S.W., Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol 83 (2011), 1178–1186.
89. [89] Fung, J., Lai, C.L., Young, J., Wong, D.K., Yuen, J., Seto, W.K., et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 106 (2011), 1766–1773.
90. [90] Singh, A.K., Sharma, M.K., Hissar, S.S., Gupta, E., Sarin, S.K., Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment. J Viral Hepat 21 (2014), 439–446.
91. [91] Cai, W., Xie, Q., An, B., Wang, H., Zhou, X., Zhao, G., et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 48 (2010), 22–26.
92. [92] Lee, J.M., Ahn, S.H., Kim, H.S., Park, H., Chang, H.Y., Kim, D.Y., et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 53 (2011), 1486–1493.
93. [93] Hadziyannis, S.J., Sevastianos, V., Rapti, I., Vassilopoulos, D., Hadziyannis, E., Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 143 (2012), 629–636, e1.
94. [94] Chang, M.L., Liaw, Y.F., Hadziyannis, S.J., Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 42 (2015), 243–257.
95. [95] Buti, M., Casillas, R., Riveiro-Barciela, M., Homs, M., Tabernero, D., Salcedo, M.T., et al. Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful. J Clin Virol 68 (2015), 61–68.
96. [96] Rinker, F., Honer Zu Siederdissen, C., Bremer, C.M., Bremer, B., Falk, C.S., Manns, M.P., et al. Induction of innate and adaptive immune responses after stopping NA therapy in HBeAg negative chronic hepatitis B. Z Gastroenterol, 53, 2015, 10.1055/s-0035.
97. [97] Wong, G.L., Wong, V.W., Chan, H.L., Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. J Viral Hepat 21 (2014), 825–834.
98. [98] Marcellin, P., Lau, G.K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004), 1206–1217.
99. [99] Lau, G.K., Piratvisuth, T., Luo, K.X., Marcellin, P., Thongsawat, S., Cooksley, G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005), 2682–2695.
100. [100] Janssen, H.L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U.S., Cakaloglu, Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005), 123–129.
101. [101] Chan, H.L., Leung, N.W., Hui, A.Y., Wong, V.W., Liew, C.T., Chim, A.M., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142 (2005), 240–250.
102. [102] Chan, H.L., Wong, V.W., Chim, A.M., Choi, P.C., Chan, H.Y., Hui, A.Y., et al. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 12 (2007), 815–823.
103. [103] Marcellin, P., Ahn, S.H., Ma, X., Caruntu, F.A., Tak, W.Y., Elkashab, M., et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150 (2016), 134–144, e10.
104. [104] Chan, H.L., Ahn, S.H., Chuang, W.L., Hui, A.J., Tabak, F., Mehta, R., et al. Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB). J Hepatol 62 (2015), S251–S252.
105. [105] Ning, Q., Han, M., Sun, Y., Jiang, J., Tan, D., Hou, J., et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 61 (2014), 777–784.
106. [106] Hu, P., Shang, J., Zhang, W.H., Gong, G., Yongguo, L., Chen, X., et al. Predictive value of baseline and on-treatment qHBsAg level in HBeAg positive CHB patients who switched from NUCs to pegylated interferon A-2A: A further analysis from new switch study. J Hepatol, 62, 2015, S251.
107. [107] Han, M., Jiang, J., Hou, J., Tan, D., Sun, Y., Zhao, M., et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1-year follow-up of the OSST study. Antivir Ther, 2016, 10.3851/IMP3019.
108. [108] Raimondo, G., Brunetto, M.R., Pontisso, P., Smedile, A., Maina, A.M., Saitta, C., et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 43 (2006), 100–107.
109. [109] Wiegand, S.B., Jaroszewicz, J., Potthoff, A., Honer Zu Siederdissen, C., Maasoumy, B., Deterding, K., et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-gamma-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect, 21, 2015, 710, e1–e9.
110. [110] Potthoff, A., Manns, M.P., Wedemeyer, H., Treatment of HBV/HCV coinfection. Expert Opin Pharmacother 11 (2010), 919–928.
111. [111] Takayama, H., Sato, T., Ikeda, F., Fujiki, S., Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res, 2015, 10.1111/hepr.12578.
112. [112] Jaroszewicz, J., Reiberger, T., Meyer-Olson, D., Mauss, S., Vogel, M., Ingiliz, P., et al. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS One, 7, 2012, e43143.
113. [113] Zoutendijk, R., Zaaijer, H.L., de Vries-Sluijs, T.E., Reijnders, J.G., Mulder, J.W., Kroon, F.P., et al. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis 206 (2012), 974–980.
114. [114] Maylin, S., Boyd, A., Lavocat, F., Gozlan, J., Lascoux-Combe, C., Miailhes, P., et al. Kinetics of HBs and HBe antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-HBV infected patients. AIDS 26 (2012), 939–949.
115. [115] Arendt, E., Jaroszewicz, J., Rockstroh, J., Meyer-Olson, D., Zacher, B.J., Mederacke, I., et al. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. Viral Immunol 25 (2012), 442–447.
116. [116] Strassl, R., Reiberger, T., Honsig, C., Payer, B.A., Mandorfer, M., Grabmeier-Pfistershammer, K., et al. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients. J Viral Hepat 21 (2014), 508–516.
117. [117] Hughes, S.A., Wedemeyer, H., Harrison, P.M., Hepatitis delta virus. Lancet 378 (2011), 73–85.
118. [118] Heidrich, B., Deterding, K., Tillmann, H.L., Raupach, R., Manns, M.P., Wedemeyer, H., Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat 16 (2009), 883–894.
119. [119] Heidrich, B., Serrano, B.C., Idilman, R., Kabacam, G., Bremer, B., Raupach, R., et al. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int 32 (2012), 1415–1425.
120. [120] Wedemeyer, H., Yurdaydin, C., Dalekos, G.N., Erhardt, A., Cakaloglu, Y., Degertekin, H., et al. Peginterferon plus adefovir vs. either drug alone for hepatitis delta. N Engl J Med 364 (2011), 322–331.
121. [121] Heidrich, B., Yurdaydin, C., Kabacam, G., Ratsch, B.A., Zachou, K., Bremer, B., et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60 (2014), 87–97.
122. [122] Manesis, E.K., Schina, M., Le Gal, F., Agelopoulou, O., Papaioannou, C., Kalligeros, C., et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther 12 (2007), 381–388.
123. [123] Ouzan, D., Penaranda, G., Joly, H., Halfon, P., Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta. J Hepatol 58 (2013), 1258–1259.
124. [124] Durantel, D., Zoulim, F., New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol 64 (2016), S117–S131.